A phase 1/2 study of chemosensitization with plerixafor plus G-CSF in relapsed or refractory acute myeloid leukemia

Blood Cancer J. 2017 Mar 10;7(3):e542. doi: 10.1038/bcj.2017.21.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Autografts
  • Benzylamines
  • Cyclams
  • Cytarabine / administration & dosage
  • Etoposide / administration & dosage
  • Female
  • Granulocyte Colony-Stimulating Factor / administration & dosage*
  • Hematopoietic Stem Cell Mobilization*
  • Heterocyclic Compounds / administration & dosage*
  • Humans
  • Leukemia, Myeloid, Acute / therapy*
  • Male
  • Middle Aged
  • Mitoxantrone / administration & dosage
  • Stem Cell Transplantation*

Substances

  • Benzylamines
  • Cyclams
  • Heterocyclic Compounds
  • Cytarabine
  • Granulocyte Colony-Stimulating Factor
  • Etoposide
  • Mitoxantrone
  • plerixafor

Supplementary concepts

  • MAV protocol